Study of two drugs before surgery for upper tract cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of two drugs, enfortumab vedotin and pembrolizumab, given before surgery for upper tract urothelial cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes for patients who are candidates for surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with high-grade upper tract urothelial cancer (in the kidney pelvis or ureter).
- You are healthy enough for surgery and have not had previous immune therapy or certain other cancer treatments.
- You are 18 years or older and able to perform daily activities with minimal help (ECOG 0-1).
- You have adequate organ function and no active infections or certain eye conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether durvalumab (an immunotherapy) given with chemotherapy before surgery can improve outcomes for people with high-risk cancer in the kidney pelvis or ureter. It is mainly looking at safety and effectiveness in shrinking or controlling the cancer before treatment continues.
This trial tests a combination of two drugs (enfortumab vedotin and pembrolizumab) given before surgery to shrink or eliminate bladder or upper tract cancer. The goal is to see if this approach reduces the chance of cancer coming back and improves outcomes.
This trial tests two drugs, enfortumab vedotin and pembrolizumab, given before surgery to remove the bladder or ureter in people with advanced bladder or upper urinary tract cancer that has spread to lymph nodes or other organs. The goal is to see if this treatment helps shrink the cancer and improves outcomes.
This Phase 2 trial studies whether a combination treatment can control high-grade upper tract urothelial cancer without removing the kidney and ureter (radical nephroureterectomy). It may help people who must avoid surgery or choose not to have it because of medical risk.
This Phase 2 study tests giving pembrolizumab (an immune therapy) and enfortumab vedotin (an antibody-drug medicine) before and after surgery to remove high-risk upper urinary tract cancer. The goal is to lower the chance the cancer comes back.
This trial tests a two-drug combination (pembrolizumab and enfortumab vedotin) followed by maintenance pembrolizumab for people with advanced bladder cancer that has not been treated before. The goal is to see if this approach helps control the cancer for longer.
Hear when a new Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.